Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Table 1 Comparison of the clinical outcomes between the two study groups

Group	CR, n (%)	PR, n (%)	SD, n (%)	PD, n (%)	ORR (%)
FLOT group (n = 42)	0 (0.00)	23 (54.76)	14 (33.33)	5 (11.90)	54.76
SOX group (n = 42)	0 (0.00)	14 (33.33)	15 (35.71)	13 (30.95)	33.33

CR: Complete remission; PR: Partial remission; SD: Stability; PD: Progression; ORR: Objective response rate.

Table 2 Comparison of the tumor marker levels between the two groups before and after treatment (mean ± SD)

Group	CEA (ng/mL)		CA199 (U/mL)		TPS (U/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
FLOT group (n = 42)	40.16 ± 8.84	33.79 ± 5.76a	45.76 ± 10.14	24.07 ± 4.67a	160.27 ± 31.69	47.63 ± 5.09a
SOX group (n = 42)	39.41 ± 8.23	37.31 ± 7.64a	46.51 ± 10.63	29.74 ± 6.52a	162.34 ± 27.32	62.31 ± 7.62a
t-value	0.402	2.384	0.331	4.582	0.321	10.382
P value	> 0.05	< 0.05	> 0.05	< 0.05	> 0.05	< 0.05

^aP < 0.05, when compared with the pre-treatment group.

CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; TPS: Peptide tissue antigen.

Table 3 Comparison of the adverse reactions between the two study groups, n (%)

Group	Level	Skin reactions on hands and feet	Peripheral neuritis	Vomiting	Diarrhea	Abnormal liver function	Leukopenia
FLOT group (n = 42)	Level 0 to 2; Level 3 & 4	41 (97.62); 1 (2.38)	41 (97.62); 1 (2.38)	38 (90.48); 4 (9.52)	39 (92.86); 3 (7.14)	40 (95.24); 2 (4.76)	25 (59.52); 17 (40.48)
SOX group (n = 42)	Level 0 to 2; Level 3 & 4	34 (80.95); 8 (19.05)a	42 (100.00); 0 (0.00)	40 (95.24); 2 (4.76)	40 (95.24); 2 (4.76)	41 (97.62); 1 (2.38)	35 (83.33); 7 (16.67)a

^aP < 0.05, when compared with the FLOT group (grades 3 and 4).

Table 4 Cox regression analysis to predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Related factors	HR	95%CI	Standard error	P value
bFGF (pg/mL)	2.917	1.066-7.978	0.513	0.037
IL-1β (pg/mL)	1.155	1.062-3.124	0.563	0.078
TNF-α (μg/L)	1.037	0.669-2.140	0.436	0.092
Single organ transfer	0.073	0.019-1.320	0.721	0.541
Multi-organ metastases	1.024	0.725-1.925	0.547	0.354
Tumor location	1.093	0.763-1.724	0.852	0.320
Tissue differentiation	1.115	0.975-1.520	0.973	0.163

bFGF: Basic fibroblast growth factor; IL-1β: Interleukin-1β; TNF-α: Tumour necrosis factor α.